Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CDA | P32320 | 1/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685622 | 1.00 | MAPT (0.51) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7764746 | 1.00 | MAPT (0.51) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31685600 | 0.86 | TK2 (0.44) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL635155 | 0.85 | MAPT (0.47) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5903970 | 0.85 | PYGM (0.49) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7640658 | 0.85 | MAPT (0.47) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5903974 | 0.85 | PYGM (0.49) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2908553 | 0.85 | MAPT (0.50) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12718534 | 0.85 | TYMP (0.53) | MAPTCDATYMPPYGMSLC5A2 | |
| SCHEMBL12718548 | 0.85 | TYMP (0.53) | MAPTCDATYMPPYGMSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118866-A1 | GPC3-SPECIFIC ANTIBODIES, BINDING DOMAINS, AND RELATED PROTEINS AND USES THEREOF | MODERNATX, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024112568-A1 | ANTISENSE OLIGOMER (ASO) AS AN INHIBITOR OF LIVER FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| WO-2024097639-A1 | HSA-BINDING ANTIBODIES AND BINDING PROTEINS AND USES THEREOF | MODERNATX, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024044741-A2 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5'-CAPPED OLIGONUCLEOTIDES | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023235749-A2 | RNA ADJUVANTS, METHODS AND USES THEREOF | FLAG BIO, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023014974-A1 | DOUBLE STRANDED MRNA VACCINES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220192997-A1 | VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-06-23 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3053585-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2918275-B1 | Alternative nucleic acid molecules and uses thereof | MODERNA THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPT 3290/4885CDA 200/4885SLC28A1 302/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MAPT 3517/4885CDA 46/4885SLC28A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.